Processa Pharmaceuticals announces preclinical data for NGC-Iri

Processa Pharmaceuticals announces positive data from preclinical studies that support the potential for NGC-Iri to have improved efficacy and a better side effect profile compared with the commonly used FDA-approved cancer treatments irinotecan and Onivyde. Next Generation irinotecan is a prodrug of SN-38, which is the active anticancer metabolite of irinotecan. The two studies demonstrated that in mice that were administered the same amount of SN-38: Accumulation of SN-38 in the tumor compared with other tissues, such as muscle, was greater after NGC-Iri administration than after irinotecan or Onivyde administration, as demonstrated by the tumor-to-muscle ratio of approximately 200 for NGC-Iri and less than 15 for irinotecan and Onivyde; More SN-38 accumulated in the tumor after NGC-Iri administration than after irinotecan or Onivyde administration, as demonstrated by the tumor-to-plasma ratio being approximately 10 for NGC-Iri and less than 7 for irinotecan and Onivyde; and Less SN-38 accumulated in non-cancer tissues, such as muscle, after NGC-Iri administration than after irinotecan or Onivyde administration, as demonstrated by the muscle-to-plasma ratio being less than 0.10 for NGC-Iri and greater than 0.4 for irinotecan and Onivyde, supporting the potential for a better NGC-Iri safety profile.